BRPI0516975A - anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno - Google Patents
anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgenoInfo
- Publication number
- BRPI0516975A BRPI0516975A BRPI0516975-5A BRPI0516975A BRPI0516975A BR PI0516975 A BRPI0516975 A BR PI0516975A BR PI0516975 A BRPI0516975 A BR PI0516975A BR PI0516975 A BRPI0516975 A BR PI0516975A
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- antigen
- binding fragment
- immunoconjugate
- hybridoma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
Abstract
ANTICORPO OU SEU FRAGMENTO DE LIGAçãO A ANTìGENO, COMPOSIçãO FARMACêUTICA, IMUNOCONJUGADO, HIBRIDOMA, ANTICORPO MONOCLONAL, E, USO DE UM ANTICORPO OU SEU FRAGMENTO DE LIGAçãO A ANTìGENO. A presente invenção refere-se ao bloqueio, à redução, à antagonização ou à neutralização da atividade de moléculas de polipeptídeo IL-20, IL-22, ou de ambas as moléculas de polipeptídeo IL-20 e IL-22. IL-20 e IL-22 são citocinas que estão envolvidas em processos inflamatórios e doenças de humano. IL-22RA (zcytorl 1) é um receptor comum para IL-20 e IL-22. A presente invenção inclui anticorpos anti-IL-22RA e parceiros de ligação, bem como métodos para antagonizar IL-22 ou ambas IL-20 e IL-22 usando tais anticorpos e parceiros de ligação.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62155304P | 2004-10-22 | 2004-10-22 | |
PCT/US2005/037821 WO2006047249A1 (en) | 2004-10-22 | 2005-10-21 | Anti-il-22ra antibodies and binding partners and methods of using in inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0516975A true BRPI0516975A (pt) | 2008-09-30 |
Family
ID=35871017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0516975-5A BRPI0516975A (pt) | 2004-10-22 | 2005-10-21 | anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno |
Country Status (22)
Country | Link |
---|---|
US (5) | US7537761B2 (pt) |
EP (1) | EP1812476B1 (pt) |
JP (1) | JP4898691B2 (pt) |
KR (1) | KR101238684B1 (pt) |
CN (1) | CN101198625A (pt) |
AT (1) | ATE474856T1 (pt) |
AU (1) | AU2005299809B2 (pt) |
BR (1) | BRPI0516975A (pt) |
CA (1) | CA2584157C (pt) |
CY (1) | CY1110843T1 (pt) |
DE (1) | DE602005022475D1 (pt) |
DK (1) | DK1812476T3 (pt) |
EA (1) | EA015706B1 (pt) |
ES (1) | ES2347672T3 (pt) |
HK (1) | HK1110333A1 (pt) |
IL (2) | IL182503A (pt) |
MX (1) | MX2007004770A (pt) |
NO (1) | NO20072602L (pt) |
PT (1) | PT1812476E (pt) |
UA (1) | UA96122C2 (pt) |
WO (1) | WO2006047249A1 (pt) |
ZA (1) | ZA200704125B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965704A (en) * | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
CA2418950A1 (en) * | 2000-08-08 | 2002-02-14 | Zymogenetics, Inc. | Soluble zcytor 11 cytokine receptors |
EP1606317B1 (en) * | 2003-03-24 | 2010-07-28 | ZymoGenetics, Inc. | Anti-il-22ra antibodies and binding partners and methods of using in inflammation |
EP2143733A1 (en) * | 2003-11-21 | 2010-01-13 | ZymoGenetics, Inc. | ANTI-IL-20 antibodies and binding partners and methods of using in inflammation |
ATE474856T1 (de) | 2004-10-22 | 2010-08-15 | Zymogenetics Inc | Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen |
JP2009518314A (ja) * | 2005-12-02 | 2009-05-07 | ジェネンテック・インコーポレーテッド | Il−22に結合する抗体およびil−22rに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法 |
WO2011047153A1 (en) * | 2009-10-15 | 2011-04-21 | President And Fellows Of Harvard College | Methods for modulating autoimmunity |
EP2512511B1 (en) | 2009-11-19 | 2015-01-07 | Merck Serono S.A. | Humanized antibodies against human il-22ra |
EP3216462A3 (en) | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Stable antibody containing compositions |
CA2800188A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
AU2012204574B2 (en) | 2011-01-04 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating age-related macular degeneration |
CN103596979B (zh) | 2011-03-16 | 2018-01-26 | 阿尔金-X有限公司 | 针对cd70的抗体 |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
CN109328069B (zh) * | 2016-04-15 | 2023-09-01 | 亿一生物医药开发(上海)有限公司 | Il-22在治疗坏死性小肠结肠炎中的用途 |
EP3464357A1 (en) | 2016-05-24 | 2019-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections |
GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
KR102098294B1 (ko) * | 2016-11-24 | 2020-04-07 | 주식회사 휴벳바이오 | 질환의 진단용 조성물 |
KR20210019464A (ko) | 2018-06-05 | 2021-02-22 | 바이오아트라, 인코퍼레이티드 | 항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도 |
CN110078832B (zh) * | 2019-04-18 | 2021-12-14 | 江南大学 | 一类基于ZZ domain的二抗及其制备方法和应用 |
US20240083995A1 (en) * | 2021-03-02 | 2024-03-14 | Laurie H. Glimcher | Methods of treating red blood cell disorders |
WO2024184333A1 (en) | 2023-03-08 | 2024-09-12 | Leo Pharma A/S | Il-22r antibody for use in treating atopic dermatitis |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654090A (en) * | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
NZ212437A (en) | 1985-06-17 | 1992-06-25 | Mark Philip Best | Site-directed antibody conjugates, and their preparation |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5436155A (en) | 1991-12-31 | 1995-07-25 | Arch Development Corporation | Isolated DNA encoding a somatostatin receptor |
US5789192A (en) | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
WO2000077037A2 (en) | 1999-06-15 | 2000-12-21 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
IL127891A0 (en) | 1996-07-12 | 1999-10-28 | Genentech Inc | Chimeric heteromultimeter adhesins |
US5843697A (en) | 1996-07-17 | 1998-12-01 | University Of Medicine And Dentistry Of New Jersey | Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein |
US5985614A (en) | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
WO1999046281A2 (en) | 1998-03-10 | 1999-09-16 | Genentech, Inc. | Novel polypeptides and nucleic acids encoding the same |
US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
EP1012260A4 (en) | 1997-07-16 | 2001-05-09 | Human Genome Sciences Inc | INTERLEUKINE-20 |
US6486301B1 (en) | 1997-07-16 | 2002-11-26 | Human Genome Sciences, Inc. | Interleukin-20 |
US5965704A (en) | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
EP1009762A2 (en) | 1997-08-06 | 2000-06-21 | ZymoGenetics, Inc. | Lipocalin homologs |
US6551799B2 (en) | 1999-12-07 | 2003-04-22 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
BR9814904A (pt) | 1997-11-26 | 2000-10-03 | Zymogenetics Inc | Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo. |
US6576743B1 (en) | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
AU737592B2 (en) | 1998-01-23 | 2001-08-23 | Immunex Corporation | Il-18 receptors |
AU2871899A (en) | 1998-03-09 | 1999-09-27 | Schering Corporation | Human receptor proteins; related reagents and methods |
US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
US6982320B2 (en) | 1998-03-19 | 2006-01-03 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
WO1999061630A2 (en) | 1998-05-26 | 1999-12-02 | Regeneron Pharmaceuticals, Inc. | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
ES2207278T3 (es) | 1998-07-28 | 2004-05-16 | Micromet Ag | Heterominicuerpos. |
CA2339043A1 (en) | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6274710B1 (en) | 1998-10-26 | 2001-08-14 | Ludwig Institute For Cancer Research | Antibodies which specifically bind T Cell inducible factors (TIFs) |
JP3769189B2 (ja) | 1998-10-26 | 2006-04-19 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | T細胞誘導性因子(tif)をコードする単離された核酸分子、コードされたタンパク質およびその使用 |
EP1141008A1 (en) | 1998-12-31 | 2001-10-10 | Millennium Pharmaceuticals, Inc. | Class ii cytokine receptor-like proteins and nucleic acids encoding them |
MXPA01010883A (es) | 1999-04-28 | 2002-10-31 | Inst Genetics Llc | Proteinas gil-19/ae289 humanas y polinucleotidos que las codifican. |
WO2000070049A2 (en) | 1999-05-19 | 2000-11-23 | Incyte Genomics, Inc. | Extracellular signaling molecules |
AU5047600A (en) | 1999-05-27 | 2000-12-18 | Schering Corporation | Mammalian interleukin-10 homologs: il-d110 and il-d210 |
AU2883700A (en) | 1999-06-23 | 2001-01-09 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001004304A1 (en) | 1999-07-07 | 2001-01-18 | Zymogenetics, Inc. | Human cytokine receptor |
AU7573000A (en) | 1999-09-01 | 2001-03-26 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU1919201A (en) | 1999-11-18 | 2001-05-30 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
WO2001040467A1 (en) | 1999-12-03 | 2001-06-07 | Zymogenetics, Inc. | Human cytokine receptor |
AU2458001A (en) | 1999-12-23 | 2001-07-03 | Zymogenetics Inc. | Method for treating inflammation |
ATE459716T1 (de) | 1999-12-23 | 2010-03-15 | Zymogenetics Inc | Zytokin zcyt018 |
DE60040240D1 (de) | 1999-12-23 | 2008-10-23 | Zymogenetics Inc | Löslicher interleukin-20 rezeptor |
US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
NZ523122A (en) | 2000-06-22 | 2004-06-25 | Smithkline Beecham Corp | Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases |
JP2002015498A (ja) | 2000-06-29 | 2002-01-18 | Fujitsu Ltd | センス電流の設定方法 |
CA2418950A1 (en) | 2000-08-08 | 2002-02-14 | Zymogenetics, Inc. | Soluble zcytor 11 cytokine receptors |
WO2002020569A2 (en) | 2000-09-08 | 2002-03-14 | Schering Corporation | Mammalian genes; related reagents and methods |
ES2267814T3 (es) | 2000-09-15 | 2007-03-16 | Zymogenetics, Inc. | Metodo para tratar la inflamacion. |
US7268223B2 (en) | 2000-09-22 | 2007-09-11 | Wyeth | Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
EP1191035A3 (de) | 2000-09-25 | 2002-04-17 | Schering Aktiengesellschaft | Drei Mitglieder der Zytokinrezeptorfamilie Klasse II |
US20030022827A1 (en) | 2000-09-25 | 2003-01-30 | Bertram Weiss | Three new members of the cytokine receptor family class 2 |
NZ527087A (en) | 2001-01-12 | 2008-09-26 | Genetics Inst Llc | Type 2 cytokine receptor and nucleic acids encoding same |
WO2002058724A2 (en) | 2001-01-26 | 2002-08-01 | Eli Lilly And Company | Use of lp82 to treat body weight disorders |
JP2005510451A (ja) | 2001-02-23 | 2005-04-21 | ジェネティクス インスティテュート,エルエルシー | 炎症性障害を治療するための組成物及び方法 |
CA2433933A1 (en) | 2001-02-28 | 2002-09-12 | Eli Lilly And Company | Use of lp82 to treat hematopoietic disorders |
AU2002305944A1 (en) | 2001-03-02 | 2002-09-19 | Zymogenetics, Inc. | Mouse cytokine receptor |
EA005496B1 (ru) * | 2001-03-09 | 2005-02-24 | Займодженетикс, Инк. | Растворимый гетеродимерный рецептор цитокина |
US20040086908A1 (en) | 2002-03-07 | 2004-05-06 | Chandrasekher Yasmin A. | Soluble heterodimeric cytokine receptor |
US20030099608A1 (en) | 2001-03-27 | 2003-05-29 | Presnell Scott R. | Human cytokine receptor |
EP1392359B2 (en) | 2001-05-11 | 2013-03-13 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
WO2003035096A1 (en) | 2001-10-22 | 2003-05-01 | Eli Lilly And Company | Soluble proteins that inhibit cytokine signal transduction pathways |
DE10154579A1 (de) | 2001-11-07 | 2003-05-28 | Medigene Ag | Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen |
PT1531843E (pt) | 2001-12-17 | 2011-10-27 | Zymogenetics Inc | Método para tratar o cancro cervical |
US20040236075A1 (en) | 2002-07-24 | 2004-11-25 | Laure Dumoutier | Novel glass II cytokine receptors, and uses thereof |
EP1606317B1 (en) | 2003-03-24 | 2010-07-28 | ZymoGenetics, Inc. | Anti-il-22ra antibodies and binding partners and methods of using in inflammation |
EP2143733A1 (en) | 2003-11-21 | 2010-01-13 | ZymoGenetics, Inc. | ANTI-IL-20 antibodies and binding partners and methods of using in inflammation |
ATE474856T1 (de) | 2004-10-22 | 2010-08-15 | Zymogenetics Inc | Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen |
EP2512511B1 (en) * | 2009-11-19 | 2015-01-07 | Merck Serono S.A. | Humanized antibodies against human il-22ra |
-
2005
- 2005-10-21 AT AT05816060T patent/ATE474856T1/de active
- 2005-10-21 KR KR1020077011655A patent/KR101238684B1/ko not_active IP Right Cessation
- 2005-10-21 AU AU2005299809A patent/AU2005299809B2/en not_active Ceased
- 2005-10-21 MX MX2007004770A patent/MX2007004770A/es active IP Right Grant
- 2005-10-21 PT PT05816060T patent/PT1812476E/pt unknown
- 2005-10-21 EP EP05816060A patent/EP1812476B1/en active Active
- 2005-10-21 EA EA200700916A patent/EA015706B1/ru not_active IP Right Cessation
- 2005-10-21 JP JP2007538050A patent/JP4898691B2/ja not_active Expired - Fee Related
- 2005-10-21 CN CNA2005800413287A patent/CN101198625A/zh active Pending
- 2005-10-21 BR BRPI0516975-5A patent/BRPI0516975A/pt not_active IP Right Cessation
- 2005-10-21 UA UAA200705409A patent/UA96122C2/ru unknown
- 2005-10-21 CA CA2584157A patent/CA2584157C/en not_active Expired - Fee Related
- 2005-10-21 ES ES05816060T patent/ES2347672T3/es active Active
- 2005-10-21 WO PCT/US2005/037821 patent/WO2006047249A1/en active Application Filing
- 2005-10-21 DK DK05816060.7T patent/DK1812476T3/da active
- 2005-10-21 DE DE602005022475T patent/DE602005022475D1/de active Active
- 2005-10-21 US US11/256,499 patent/US7537761B2/en active Active
-
2007
- 2007-04-12 IL IL182503A patent/IL182503A/en not_active IP Right Cessation
- 2007-05-21 NO NO20072602A patent/NO20072602L/no not_active Application Discontinuation
- 2007-05-22 ZA ZA200704125A patent/ZA200704125B/xx unknown
-
2008
- 2008-01-25 HK HK08101055.2A patent/HK1110333A1/xx not_active IP Right Cessation
-
2009
- 2009-04-14 US US12/423,699 patent/US8124088B2/en not_active Expired - Fee Related
- 2009-08-12 US US12/540,084 patent/US7871616B2/en active Active
-
2010
- 2010-07-22 IL IL207146A patent/IL207146A/en not_active IP Right Cessation
- 2010-10-18 CY CY20101100932T patent/CY1110843T1/el unknown
-
2012
- 2012-01-12 US US13/349,380 patent/US8536309B2/en not_active Expired - Fee Related
-
2013
- 2013-08-06 US US13/960,556 patent/US20130315919A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0516975A (pt) | anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno | |
EA200501505A1 (ru) | Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях | |
RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
NO20070153L (no) | Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon | |
BRPI0607486A2 (pt) | anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos | |
TR201901929T4 (tr) | TGFBeta'ya antikorlar. | |
NZ712762A (en) | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r | |
UA115964C2 (uk) | Інтерлейкін-13-зв'язувальний білок | |
EA200870130A1 (ru) | Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6 | |
DE602006013029D1 (de) | Anti-egfr-antikörper | |
MA31899B1 (fr) | Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant | |
WO2006086396A3 (en) | Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation | |
GEP20115226B (en) | P-cadherin antibodies | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
WO2008134659A3 (en) | Antagonists to il-17a, il-17f, and il-23p19 and methods of use | |
MA29226B1 (fr) | Anticorps diriges contre le recepteur alpha 1 de il-13 et leurs utilisations | |
HUP0300423A2 (hu) | Emberi interleukin-18-at megkötni képes antitestek és ezek előállítására és alkalmazására szolgáló eljárások | |
BR9907743A (pt) | Anticorpos contra a il-12 humana | |
ATE523523T1 (de) | Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung | |
WO2023159187A3 (en) | Anti-sars-cov2 spike (s) antibodies and uses thereof | |
MA37523A1 (fr) | Protéines de liaison à l'antigène st2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |